Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$159.69 USD

159.69
4,765,963

+0.16 (0.10%)

Updated Oct 8, 2024 04:00 PM ET

After-Market: $159.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Ryan McQueeney headshot

Upcoming Consumer Earnings Reports to Watch: JNJ, F, SBUX

Fourth-quarter earnings season is finally underway, and investors are already getting excited about the upcoming reports from market-moving tech companies like Netflix (NFLX). Make sure to keep an eye on these companies as they prepare to report during the week of January 22.

    Will J&J's (JNJ) Pharma Segment Pull Up its Q4 Earnings?

    J&J's (JNJ) pharma segment sales growth accelerated in the third quarter and we are likely to see, a continuation of the positive trend in the fourth quarter.

      The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis

      The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis

        Can These 4 Large-Cap Drug Stocks Deliver an Encore in '18?

        We present four large cap drug companies, which are expected to repeat their last year's industry beating performance in 2018.

          Amgen Gets FDA Nod to Add ENDEAVOR Data on Kyprolis Label

          Amgen (AMGN) gets an earlier-than-expected approval to include ENDEAVOR study OS data on Kyprolis label.

            Sweta Killa headshot

            Market at New Highs: Mega Cap ETFs & Stocks On A Roll

            Inside mega cap ETFs & stocks hitting all-time highs with the skyrocketing market.

              J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?

              Promising data from several pivotal studies and a rapid pipeline progress contribute to a rally in Johnson & Johnson's (JNJ) shares.

                J&J (JNJ) to Set Pharma Q4 Earnings in Motion: What's Up?

                The positive trend seen in J&J's (JNJ) pharma segment sales in Q3 is likely to continue in Q4. Strong pharma performance and contribution from acquisitions should support the top line.

                  Abbott's (ABT) Diabetes Care Unit Strong on FreeStyle Libre

                  Abbott (ABT) forges ahead with initiatives to boost diabetes care. The latest CMS recognition will widen customer base for FreeStyle Libre glucose monitoring system.

                    Sweta Killa headshot

                    After a Solid Start, What Awaits Dow ETF in Q4 Earnings?

                    How will Dow ETF perform in Q4 Earnings?

                      Big Pharma CEOs Speak About Impact of Tax Reform on M&A

                      This week, senior executives of some large drug companies discussed the impact of tax reform on mergers and acquisition and their plans to use the excess cash at the JP Morgan HealthCare conference.

                        Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs

                        Pfizer (PFE) will reportedly end R&D efforts in Alzheimer's and Parkinson's disease areas, which will result in about 300 job cuts.

                          Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod

                          Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.

                            Will J&J (JNJ) Continue to Tread Growth Path This Year?

                            Johnson & Johnson's (JNJ) stock was up last year. The positive trend is likely to continue this year as well.

                              Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?

                              AbbVie Inc. (ABBV) shares are expected to be northbound in 2018, carrying on the momentum achieved last year.

                                Portola's (PTLA) AndexXa BLA Review Period Extended by FDA

                                The FDA extends the review period of Portola's (PTLA) biologics license application for AndexXa by 90 days. Its response is now deferred to May 4, 2018 instead of the earlier Feb 3 deadline.

                                  Biogen's Alzheimer's Drug Misses Goal in Interim Analysis

                                  Biogen (BIIB) Alzheimer's candidate, BAN2401, failed to meet the criteria for success based on a 12 months interim analysis as the primary endpoint in a mid-stage trial.

                                    Minerva Initiates Phase III Study on Schizophrenia Candidate

                                    Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.

                                      Achillion's Renal Disease Candidate Gets Orphan Drug Status

                                      Achillion Pharmaceuticals' (ACHN) factor D inhibitor, ACH-4471, gets orphan drug designation for treating C3G, a renal disease.

                                        Allergan's Vraylar Positive for Bipolar Disease in Phase III

                                        Allergan (AGN) releases positive top-line results from a phase III study on Vraylar for treatment of bipolar I depression. The trial meets its primary endpoints with significant progress in patients.

                                          3 Low-Volatility ETFs for Your Portfolio

                                          Low-volatility ETFs might seem attractive to investors, as GOP Senate majority slims.

                                            Pfizer's Arthritis Drug Gets FDA Nod for Label Expansion

                                            The FDA approves label expansion of Pfizer's (PFE) JAK inhibitor Xeljanz for two doses on an impressive data from two phase III studies.

                                              The Zacks Analyst Blog Highlights: Microsoft, Johnson & Johnson, ExxonMobil, American Airlines and Honda

                                              The Zacks Analyst Blog Highlights: Microsoft, Johnson & Johnson, ExxonMobil, American Airlines and Honda

                                                Pfizer's Second Biosimilar of Remicade Receives FDA Approval

                                                The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.

                                                  Mark Vickery headshot

                                                  Top Analyst Reports for Microsoft, Johnson & Johnson & ExxonMobil

                                                  Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Johnson & Johnson (JNJ) and ExxonMobil (XOM).